Cosmos Health Advances Patent Protection for Innovative Hydrogel Weight Management Technology in Key Global Markets

Cosmos Health Inc. (NASDAQ:COSM), a diversified global healthcare group, announced on June 25, 2026, that its wholly owned subsidiary Cana Laboratories S.A. has advanced the international patent application WO2025108566A1, titled "Hydrogel for Body Weight Management," into the European regional phase and the national phases in the United States, Australia, and Canada. This development follows Cana's acquisition of the patent application from Cloudpharm P.C. on June 8, 2026, thereby consolidating full intellectual property ownership within Cosmos Health without any licensing fees or third-party dependencies.

The patent application covers a proprietary hydrogel technology developed to support body weight management through a mechanical mechanism that involves no systemic absorption. Administered as a capsule before meals, the dried hydrogel absorbs water in the stomach and expands over 100-fold into soft gel pieces. This expansion occupies stomach volume to promote satiety, subsequently passing naturally through the gastrointestinal tract.

Cosmos Health has undertaken a disciplined research and development program spanning over three years, beginning in November 2022. The initial phase focused on developing biocompatible three-dimensional spatial fillers derived from natural ingredients aimed at increasing satiety and reducing food intake. By June 2023, the company completed the second development phase, optimizing the hydrogel formulation.

In December 2023, Cosmos Health filed the patent application for its obesity and weight management product. The company then completed pilot production and scale-up phases by July 2024, advancing the product into its final development stage.

The strategic acquisition of the CCX0722 patent application from Cloudpharm in June 2026 marked a pivotal moment, granting Cosmos Health outright ownership of the technology. This ownership enables the company to pursue multiple pathways for value creation, including licensing, co-development, and strategic partnerships.

Cosmos Health’s methodical approach has prioritized long-term commercial viability over rapid advancement. This has included careful selection of manufacturing sites, technology transfer, thorough evaluation of regulatory pathways, and resolution of technical challenges encountered during scale-up. The company views these steps as essential to establishing a robust, defensible, and commercially viable platform.

The advancement of the international patent application into major healthcare markets aligns with the company’s broader intellectual property strategy. The global weight management market is estimated at $190.6 billion in 2025 and is projected to grow to $562.2 billion by 2033, with a compound annual growth rate of 14.2%. As obesity becomes an increasingly capital-intensive healthcare category, Cosmos Health aims to position CCX0722 as a strategically significant asset within this expanding sector.

With the patent filings now underway in the United States, Europe, Australia, and Canada, Cosmos Health continues to evaluate the development and commercialization potential of its hydrogel platform. The company’s efforts to secure comprehensive IP protection represent a critical milestone in advancing its proprietary technology within the global healthcare landscape.